GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Inventories, Raw Materials & Components

NetraMark Holdings (XCNQ:AIAI) Inventories, Raw Materials & Components : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Inventories, Raw Materials & Components?

NetraMark Holdings's inventories, raw materials & components for the quarter that ended in Mar. 2024 was C$0.00 Mil.


NetraMark Holdings Inventories, Raw Materials & Components Historical Data

The historical data trend for NetraMark Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Inventories, Raw Materials & Components Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Inventories, Raw Materials & Components
- - - -

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NetraMark Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines